Cartesian Therapeutics RNAC
NASDAQ RNAC
$7.24 +0.03 (+0.42%)
At close: Sep 29, 2026 · 4:00 PM EDT

Cartesian Therapeutics (RNAC) EV to EBITDA (2022)

Updated

Cartesian Therapeutics' (RNAC) EV to EBITDA came in at 319.34 for Q4 2022, up 23.5% from the prior quarter.

Analysis

Cartesian Therapeutics (RNAC) EV to EBITDA (2022) Analysis & Trends

Since Q1 2022, Cartesian Therapeutics has reported EV to EBITDA for 4 quarters.

  • According to Business Quant data, EV to EBITDA for the three prior quarters was 258.50 (Q3 2022), 207.95 (Q2 2022) and 303.61 (Q1 2022).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Cartesian Therapeutics 216.57 Mn 216.57 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 319.34
Sep 30, 2022 258.50
Jun 30, 2022 207.95
Mar 31, 2022 303.61
API Access

Cartesian Therapeutics EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=RNAC&period=max&api_key=YOUR_API_KEY